Icelandic Medicines Agency
Pharmacovigilance Risk Assessment Committee (PRAC), October meeting highlights
7th October 2026
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety signals, risk management plans, periodic safety update reports and post-authorisation safety studies.
The Committee did not start or conclude any referral procedures. Information on ongoing safety referrals is provided in the ‘Ongoing referrals’ table below.
Information on all topics discussed by the PRAC September 28th - October 1st is available in the agenda.